TICKERNERD
Menu
ORMPORMPHealthcare · Biotechnology

ORMP Stock Forecast: Oramed Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$4.14
−0.72% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$173.5M
Ticker Nerd rank
74 / 100
Median analyst target
$7.00
Analysts covering
0
Revenue$0.0
Operating income−$2.8M
Net income$78.2M
Free cash flow−$202K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.3%
1M
−11.3%
YTD
+55.9%
1Y
+88.2%
From 52W high
−22.5%
From 52W low
+102.8%
$2.04
$5.34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ORMP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oramed Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
84
Volatility
78
Quality
75
Value
73
Size
69
Growth
62
Issuance
61
Revisions
51
Accruals
10

Momentum (84): The shares have been drifting up relative to others.

Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ORMP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ORMP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26ORMPHigh $7.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
20 May 2024HC Wainwright & Co.ReiteratesNeutral—
17 May 2023Canaccord GenuityMaintainsHold—
17 Jan 2023HC Wainwright & Co.DowngradeNeutral—
12 Jan 2023Canaccord GenuityDowngradeHold—
16 May 2022Aegis CapitalMaintainsBuy—
18 Feb 2022Cantor FitzgeraldInitiatesOverweight—
30 Nov 2021HC Wainwright & Co.MaintainsBuy—
29 Nov 2021HC Wainwright & Co.MaintainsBuy—
2 Nov 2021Aegis CapitalMaintainsBuy—
29 July 2021Canaccord GenuityMaintainsBuy—
8 June 2021Aegis CapitalMaintainsBuy—
20 Apr 2021Canaccord GenuityInitiatesBuy—
9 Feb 2021National Securities CorporationInitiatesBuy—
27 Jan 2021Aegis CapitalMaintainsBuy—
13 July 2020HC Wainwright & Co.ReiteratesBuy—
22 June 2020HC Wainwright & Co.MaintainsBuy—
11 Sept 2019Ladenburg ThalmannInitiatesBuy—
19 Nov 2015FBR CapitalInitiatesOutperform—
1 Oct 2015H.C. WainwrightInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ORMP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ORMP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Oramed Pharmaceuticals, Inc. returned +88.2% against +17.5% for the S&P 500, dividends included.

ORMP vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26ORMPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ORMP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Oramed Pharmaceuticals, Inc. (ORMP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.0×

Cheaper than 70% of US stocks

Price / sales
86.7×

Cheaper than 4% of US stocks

Price / book
0.5×

Cheaper than 83% of US stocks

EV / EBITDA
−8.9×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
488.2%

Higher than 95% of US stocks

Gross margin
—
Operating margin
3766.2%

Higher than 99% of US stocks

Net margin
0.7%

Higher than 49% of US stocks

Returns & dividend
Return on equity
74.2%

Higher than 95% of US stocks

Return on assets
−3.4%

Higher than 34% of US stocks

Dividend yield
5.9%

Higher than 94% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Oramed Pharmaceuticals, Inc. (ORMP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oramed Pharmaceuticals, Inc. has a market value of $173.5M and an enterprise value of $127.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: $174.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$7.1M.

  • Shares outstanding: 41.3M.

  • Trailing P/E: 1.0×; forward P/E: −52.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 5.87%, paying out 6% of earnings.

  • Oramed Pharmaceuticals, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

ORMP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ORMPOramed Pharmaceuticals, Inc.$173.5M
74
WHWKWhitehawk Therapeutics, Inc.$169.3M
69
RNAAtrium Therapeutics, Inc.$171.1M
5
NGENNervGen Pharma Corp.$168.3M
23
STROSutro Biopharma, Inc.$172.4M
77
DTILPrecision BioSciences, Inc.$166.4M
67
VRXAVERAXA Biotech AG$164.0M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oramed Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ORMP news & analysis

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More

Seeking Alpha · 11 Sept 2026positive

Oramed Pharmaceuticals continues to hold a Hold rating as it shifts from drug development to strategic investments. The company has seen strong returns from its stakes in Lifeward, Scilex, and Alpha Tau Medical, including a near tripling of its $38.2 million Alpha Tau investment and solid loan recovery from Scilex, while Alpha DaRT faces clinical and regulatory risks.

Why it matters — ORMP watchers would care because the company's investment portfolio—particularly its rapidly growing Alpha Tau Medical stake—is now a major driver of asset value and diversification for the company.

FAQ

Frequently asked questions about ORMP stock

How does Ticker Nerd's model rank ORMP?

As at 14 Oct 2026, Oramed Pharmaceuticals, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).

What is the ORMP stock forecast for 2030?

No analyst covering Oramed Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.

How has ORMP stock performed over the past year?

Oramed Pharmaceuticals, Inc. returned +88.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oramed Pharmaceuticals, Inc. do?

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on oral drug delivery solutions for medications that are traditionally administered by injection.

What is the latest news on ORMP?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More". Oramed Pharmaceuticals continues to hold a Hold rating as it shifts from drug development to strategic investments. The company has seen strong returns from its stakes in Lifeward, Scilex, and Alpha Tau Medical, including a near tripling of its $38.2 million Alpha Tau investment and solid loan recovery from Scilex, while Alpha DaRT faces clinical and regulatory risks.

Company

About Oramed Pharmaceuticals, Inc.

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on oral drug delivery solutions for medications that are traditionally administered by injection. The company develops proprietary technologies designed to make therapeutic proteins and peptides easier to administer in capsule form, with a particular emphasis on diabetes-related treatments and other biologic therapies. Its current product and development portfolio includes oral insulin programs, along with partnering and licensing activities that support broader applications for its delivery platform. Oramed Pharmaceuticals Inc. also participates in strategic collaborations and investment transactions tied to its biomedical assets, reflecting a business model that combines drug development with portfolio-based value creation. Headquartered in New York, the company operates within the pharmaceuticals and biotechnology market, where oral delivery platforms can play an important role in improving convenience and expanding the usability of complex medicines.

CEO Mr. Nadav Kidron Esq. · United States · https://oramed.com